Cilengitide is a molecule designed and synthesized by the Technical University of Munich and Merck KGaA of Darmstadt. It is based on the cyclopeptide cyclo, which is selective for α1 integrin, which is essential for angiogenesis and other aspects of tumor biology.
Product name: |
Cilengitide |
Appearance: |
Whte powder |
2381089-83-2 |
204318-14-9 |
Purity: |
99% |
Grade Standard: |
Medicine Grade |
Cilengitide is a cyclized pentapeptide peptidomimetic designed to compete for the arginine-glycine-aspartic acid (RGD) peptide sequence that regulates integrin-ligand binding. Cilengitide selectively and potently blocks the ligation of theαvβ3 andαvβ5 integrins to provisional matrix proteins such as vitronectin, fibronectin, fibrinogen, von Willebrand factor, osteopontin, and others. Cilegitide inhibits angiogenesis in vitro. 10 μM Cilengitide completely inhibits attachment of BAE, BME and HUVE cells on vitronectin and fibronectin. Cilengitide inhibits in vitro angiogenesis of BAE cells on three-dimensional collagen and fibrin gels pretreated with FGF-2(or VEGF-A) with IC50 of 15 μM and 8 μM, 4 μM and 3 μM, respectively.Cilengitide blocks proliferation and induces apoptosis of endothelial cells as well as differentiation of human endothelial precursor cells (EPCs). 50 μg/mL Cilengitide completely inhibits the proliferation of human microvascular endothelial cell line HMEC-1 and leads to apoptosis in ~30% cells. 1.0 μM Cilengitide treating for 9 days inhibits the proliferation of EPCs by nearly 40%. 1 μM Cilengitide inhibits the differentiation of EPCs by more than 80% at 14 days. Cilengitide inhibits adhesion and induces apoptosis of tumor cells. 25 μg/mL Cilengitide causes detachment of DAOY cells (medulloblastoma) and U87MG cells (glioblastoma) from vitronectin and tenascin by more than 60%. 25 μg/mL Cilengitide induces a nearly 50% apoptosis rate of these cells
Cilengitide is activity against tumor growth and angiogenesis as single-agent. 100 μg Cilengitide induces a significant decrease in the number of CD 31+ vessels seen in tumors (2/high-power field) compared with control tumors (56/high-power field). 100 μg Cilengitide increases cellular apoptosis in the brain tumors of animals (2.2% apoptotic cells/high-power field) compared with those receiving the inactive peptide (1.7% cells/high-power field).
.
Related products
Product Name |
CAS No. |
Product Name |
CAS No. |
Lufenuron |
103055-07-8 |
Toltrazuril |
69004-03-1 |
Nitenpyram |
120738-89-8 |
Praziquantel/Biltricide |
55268-74-1 |
Fenbendazole |
43210-67-9 |
Tetramisole Hcl |
5086-74-8 |
Levamisole |
14769-73-4 |
Ponazuril |
9004-4-2 |
Diclazuril |
101831-37-2 |
Florfenicol |
73231-34-2 |
Albendazole |
54965-21-8 |
Mebendazole |
31431-39-7 |
Ivermectin |
70288-86-7 |
Enrofloxacin Hcl |
112732-17-9 |
RU 58841 |
154992-24-2 |
cb-03-01 |
19608-29-8 |
Biotin |
58-85-5 |
Biotinoyl tripeptide-1 |
299157-54-3 |
Finasteride |
98319-26-7 |
Dutasteride |
164656-23-9 |
Xi'an Xinlu Biotechnology Co., Ltd. is a high-end brand company focusing on the biomedical industry and integrating R&D, production and sales. It has an independent R&D center, advanced laboratory equipment and a professional R&D team, a GMP standard production workshop, a complete set of internationally advanced assembly line equipment, a preparation workshop with a cleanliness level of 100,000, as well as sophisticated testing instruments and scientific testing methods, providing solid technical support for the production of high-quality products. Through long-term R&D, production, and sales practices, it has formed its own unique product line, providing users with products of reliable quality at highly affordable prices. We strictly control quality, ensure the stability of product quality in all aspects, and win the trust of customers with high quality and high-level development.